Deep Research
Falcon
(TFRC-deep-research-falcon.md)
Falcon
(TFRC-deep-research-falcon.md)The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Research report: Human TFRC (UniProt P02786) â Transferrin receptor protein 1 (TfR1/CD71)
Scope and identity verification (critical)
The UniProt accession P02786 corresponds to the human TFRC gene product, transferrin receptor protein 1, widely referred to as TfR1 and the cell-surface marker CD71. A 2024 review on receptor-mediated transcytosis explicitly lists âTfR, CD71, TFRCâ together, confirming the symbol-to-protein mapping in the relevant physiological context (bloodâbrain barrier transport). (haqqani2024receptormediatedtranscytosisfor pages 2-3)
1) Key concepts and definitions (current understanding)
1.1 Canonical molecular function: transferrin-dependent iron uptake
TfR1 is the major cell-surface receptor that mediates cellular iron import by binding diferric transferrin (holoâTf) and internalizing the ligandâreceptor complex. A 2024 review describes TfR1 as a homodimeric transmembrane glycoprotein formed by disulfide-linked ~90 kDa subunits and emphasizes that TfR1 preferentially binds diferric transferrin to form a complex that is internalized. (li2024pathophysiologicalaspectsof pages 5-6)
1.2 Cellular mechanism and subcellular localization: clathrin-mediated endocytosis and recycling
The core trafficking cycle proceeds through clathrin-mediated endocytosis at the plasma membrane, acidic endosomes that trigger iron release, and recycling of the receptorâapotransferrin complex back to the cell surface.
* In a 2024 review, the FeâTfâTfR1 complex is described as internalized via clathrin-mediated endocytosis, followed by iron release in acidic endosomes (pH †5.5), then receptor recycling; the overall cycle is described as completing in approximately 10â20 minutes. (li2024pathophysiologicalaspectsof pages 5-6)
* A 2024 BBB transcytosis review states that receptor-mediated endocytosis at the BBB predominantly occurs via clathrin-mediated endocytosis and identifies TFRC/TfR (CD71) as a key receptor in this class. (haqqani2024receptormediatedtranscytosisfor pages 2-3)
1.3 Internalization motif (molecular definition relevant to genotype/phenotype)
A critical mechanistic concept is the tyrosine-based internalization motif âYTRFâ in the cytoplasmic tail. In a 2024 human genetics/immunology study, TfR1-mediated iron uptake is described as receptor-mediated endocytosis regulated via the YTRF motif; variants affecting this region cause defective internalization. (aba2024anovelhomozygous pages 1-2, aba2024anovelhomozygous pages 4-5)
1.4 Soluble transferrin receptor (sTfR)
The soluble transferrin receptor (sTfR) refers to a circulating form of the transferrin receptor generated by proteolytic cleavage/shedding of membrane TfR; it rises in iron deficiency and with expanded erythropoiesis because more receptor is expressed and shed. A recent synthesis notes that sTfR is clinically usefulâoften together with ferritin-based indicesâyet cutoffs are not standardized across assays and populations. (polizzi2026recentadvancesin pages 10-11)
2) Recent developments and latest research (prioritizing 2023â2024)
2.1 2024: TFRC germline variants as an inborn error of immunity (ironâimmune crosstalk)
A 2024 Journal of Clinical Immunology report identifies a new homozygous TFRC variant (c.64C>T; p.R22W) causing combined immunodeficiency (CID) and shows it produces an internalization defect similar to the previously known p.Y20H founder variant. Key mechanistic findings include:
* Impaired TfR1 internalization (approximately fourfold lower internalization in patient T cells in the reported assays) with increased steady-state surface TfR1. (aba2024anovelhomozygous pages 4-5)
* Downstream immune consequences: impaired T-cell activation (failure to upregulate CD25/ICOS), defective T- and B-cell proliferation, increased activation-induced apoptosis, restricted clonal diversity, and metabolic defects including impaired mitochondrial oxidative phosphorylation in activated helper T cells. (aba2024anovelhomozygous pages 9-12, aba2024anovelhomozygous pages 4-5)
* Clinical phenotype in the described case includes recurrent infections (e.g., sinopulmonary), bronchiectasis, chronic cytopenias (neutropenia, thrombocytopenia), microcytic anemia, hypogammaglobulinemia, and reduced NK/Treg/MAIT populations. (aba2024anovelhomozygous pages 4-5)
This line of evidence strengthens the view that TFRC is not only an iron import receptor but also a non-redundant immune-metabolic checkpoint during lymphocyte activation and expansion. (aba2024anovelhomozygous pages 9-12, aba2024anovelhomozygous pages 1-2)
2.2 2024: TFRC as a regulatory node in ferroptosis and therapy response
Multiple 2024 studies place TFRC at the intersection of iron uptake and ferroptosis (iron-dependent lipid peroxidation-driven cell death), with distinct upstream regulatory mechanisms:
(a) Aging liver ischemia/reperfusion injury (Nature Communications, Jun 2024)
* Older livers display increased oxidative stress/lipid peroxidation and increased ACSL4 and TFRC after reperfusion.
* The m6A demethylase FTO is downregulated in older livers; TFRC and ACSL4 are presented as FTO targets, with FTO overexpression mitigating injury by reducing ferroptosis via m6A-dependent regulation of mRNA stability.
* A translational angle is proposed where nicotinamide mononucleotide increases FTO activity and suppresses ferroptosis. (li2024ftodeficiencyin pages 1-2, li2024ftodeficiencyin pages 2-4)
(b) Sorafenib resistance in hepatocellular carcinoma (J Exp Clin Cancer Res, Aug 2024)
* A CCT3/ACTN4/TFRC axis is described in which CCT3 interacts with ACTN4 to impair TFRC recycling back to the plasma membrane, thereby reducing iron endocytosis and protecting cells from ferroptosis.
* CCT3 knockdown sensitizes HCC cells to sorafenib and increases sorafenib-induced ferroptosis; effects are supported by in vivo xenograft experiments. (zhu2024cct3actn4tfrcaxisprotects pages 1-2)
(c) Breast cancer adriamycin resistance (FASEB Journal, Aug 2024)
* HIF1α is shown by dual-luciferase assay to act upstream of TFRC, and increasing HIF1α increases TFRC and ferroptosis-associated markers (Fe2+, MDA).
* Ferroptosis dependence is supported by rescue with ferroptosis inhibitor Ferâ1 in the cellular model, linking TFRC-driven iron accumulation to therapy response. (yu2024hypoxiaâinduciblefactorâ1αcan pages 1-2)
Collectively, these studies update TFRCâs functional annotation from âiron receptorâ to a conditionally actionable control point for iron-dependent cell death programs in both injury and cancer contexts. (li2024ftodeficiencyin pages 1-2, zhu2024cct3actn4tfrcaxisprotects pages 1-2, yu2024hypoxiaâinduciblefactorâ1αcan pages 1-2)
3) Current applications and real-world implementations
3.1 TFRC/TfR1 targeting for bloodâbrain barrier delivery (receptor-mediated transcytosis)
TfR1 is a leading target for receptor-mediated transcytosis (RMT) strategies to shuttle biologics across the BBB.
* A 2024 review explains the RMT concept and includes TFRC/TfR among the best-studied BBB receptors; it also emphasizes that such receptors commonly internalize through clathrin-mediated endocytosis and then traffic through intracellular compartments before release on the abluminal side. (haqqani2024receptormediatedtranscytosisfor pages 2-3)
* A TfR1-focused review (2025, included here for engineering detail) highlights key design constraints for TfR1 shuttles: favoring monovalent and moderate-affinity binding, pH-dependent dissociation in early endosomes, and avoiding multivalent clustering that drives lysosomal capture; it also notes evaluation platforms such as human iPSC-derived BBB models and microvessel systems. (shen2025targetingtransferrinreceptor pages 6-8)
3.2 Cancer-targeted delivery exploiting CD71/TfR1 overexpression
A 2024 review on transferrin-based delivery catalogs multiple Tf/TfR1-targeted platforms used experimentally for tumor delivery, including Tfâdrug conjugates, Tf-modified nanoparticles, liposomes, microemulsions, and toxin conjugates, leveraging the rapid TfR1 trafficking cycle (~10â20 min) to enhance uptake. (li2024pathophysiologicalaspectsof pages 8-9, li2024pathophysiologicalaspectsof pages 6-8, li2024pathophysiologicalaspectsof pages 5-6)
A 2024 experimental nanomaterial study demonstrates an implementation conceptually aligned with TFRC biology: transferrin-derived carbon dots selectively bind CD71 on HL60 leukemia cells and trigger clathrin-dependent endocytosis, positioning such particles as candidates for imaging/biosensing and targeted uptake applications. (strickland2024cancercelltargeting pages 1-2)
4) Expert opinions / analysis from authoritative sources
4.1 âLessons learnedâ in TFRC/TfR1 BBB targeting
Authoritative BBB delivery analyses emphasize that merely binding TfR1 is insufficient; effective delivery depends on controlling intracellular trafficking fate (recycling/transcytosis vs lysosomal degradation). The design principles described (monovalency, moderate affinity, pH-sensitive dissociation, epitope selection, ligand density) reflect expert consensus in the RMT field and are intended to mitigate well-recognized issues like endosomal/lysosomal trapping and limited productive transcytosis. (shen2025targetingtransferrinreceptor pages 6-8)
4.2 TFRC as an immune-metabolic checkpoint
The 2024 CID genetics report provides mechanistic evidence supporting an expert interpretation: TFRC function is not interchangeable in activated lymphocytes because TfR1 internalization is needed to supply iron for proliferation and mitochondrial metabolism; partial rescue by exogenous iron sources reinforces the causal iron-dependence. (aba2024anovelhomozygous pages 9-12, aba2024anovelhomozygous pages 4-5)
5) Statistics and data from recent studies
5.1 sTfR as a clinical biomarker (2023 cohort with quantitative associations)
A 2023 prospective observational cohort analysis in chronic heart failure (HF) (final analyzed cohort n=215, selected for normal hemoglobin and normal systemic iron markers) used sTfR to define âtissue iron deficiencyâ (because standardized cutoffs are lacking).
* The authors define tissue iron deficiency as sTfR > 75th percentile = 1.63 mg/L; sTfR tertiles were <1.11, 1.11â1.45, and â„1.46 mg/L, with ~26% meeting the >75th percentile definition. (rasjimenez2023solubletransferrinreceptor pages 3-5, rasjimenez2023solubletransferrinreceptor media 424abe75)
* Patients meeting the tissue iron deficiency definition had markedly worse functional capacity: 6-minute walk test (6MWT) distance 206 ± 179 m vs 314 ± 155 m (p < 0.0001). (rasjimenez2023solubletransferrinreceptor pages 1-2, rasjimenez2023solubletransferrinreceptor media 424abe75)
* Quality of life was worse: Minnesota Living with HF Questionnaire overall summary score 51 ± 27 vs 39 ± 20 (p = 0.006). (rasjimenez2023solubletransferrinreceptor pages 1-2)
* Regression results: log sTfR standardized ÎČ = â0.135 (p = 0.010) in multivariable models for 6MWT distance; tissue ID (sTfR > 1.63 mg/L) multivariable standardized ÎČ = â0.176 (p = 0.001). Odds ratios for impaired exercise capacity included OR 2.8 (1.44â5.43) for tissue ID (p = 0.002). (rasjimenez2023solubletransferrinreceptor pages 5-7)
These data illustrate a real-world deployment of TFRC biology via its soluble ectodomain biomarker and underscore the practical issue that sTfR thresholds are often cohort- and assay-specific. (rasjimenez2023solubletransferrinreceptor pages 2-3, rasjimenez2023solubletransferrinreceptor pages 3-5)
Integrated summary table
| Topic | Key recent finding | Evidence type/model | Practical implication | Primary citations (pqac IDs) |
|---|---|---|---|---|
| TFRC/TfR1 core function and trafficking | Human TFRC encodes TfR1/CD71, a homodimeric type II transmembrane receptor that binds diferric transferrin, internalizes via clathrin/AP-2-mediated endocytosis, releases iron in acidic endosomes, and recycles apo-transferrin/TfR1 to the surface; the cytoplasmic YTRF motif is critical for internalization. | Mechanistic reviews and human disease-focused primary study; receptor biology and trafficking synthesis. | Establishes the primary molecular function for functional annotation: transferrin-dependent cellular iron import coupled to rapid endocytic recycling, with the YTRF motif explaining trafficking-sensitive pathogenic variants and engineering opportunities. | (aba2024anovelhomozygous pages 1-2, li2024pathophysiologicalaspectsof pages 5-6, shen2025targetingtransferrinreceptor pages 4-5, haqqani2024receptormediatedtranscytosisfor pages 2-3) |
| 2024 immune deficiency findings | A new homozygous TFRC p.R22W variant, alongside known p.Y20H, disrupts the YTRF-region internalization machinery, increases surface TfR1, impairs receptor shuttling/iron uptake, and causes combined immunodeficiency with defective T/B-cell activation, restricted clonal diversity, hypogammaglobulinemia, cytopenias, recurrent infections, and reduced NK/Treg/MAIT cells; some proliferative defects were partially rescued by exogenous iron. | 2024 human genetics and immunology study in patient cells, engineered HEK293T constructs, flow cytometry, Seahorse metabolic assays, transcriptomics. | Shows TfR1 is not only an iron receptor but a nonredundant immune-metabolic checkpoint; supports TFRC inclusion in inborn error of immunity workups and motivates iron-uptake rescue or HSCT-based management strategies. | (aba2024anovelhomozygous pages 9-12, aba2024anovelhomozygous pages 2-4, aba2024anovelhomozygous pages 1-2, aba2024anovelhomozygous pages 4-5) |
| 2024 ferroptosis-related regulatory axes | Multiple 2024 studies place TFRC as a positive ferroptosis node: reduced FTO increases m6A-dependent stability of Tfrc/Acsl4 transcripts in aged liver I/R injury; CCT3-ACTN4 limits TFRC recycling to the plasma membrane and thereby suppresses iron endocytosis/ferroptosis in sorafenib-resistant HCC; HIF1A transcriptionally upregulates TFRC in breast cancer, increasing Fe2+ and lipid peroxidation and restoring Adriamycin sensitivity. | 2024 primary mechanistic studies using mouse liver I/R models, primary hepatocytes, HCC cell lines/xenografts, breast cancer clinical samples/cell models, dual-luciferase assays, ferroptosis rescue assays. | Identifies TFRC trafficking/expression as a therapeutically actionable lever for ferroptosis modulation in cancer and ischemia-reperfusion injury, including overcoming drug resistance. | (li2024ftodeficiencyin pages 1-2, zhu2024cct3actn4tfrcaxisprotects pages 1-2, yu2024hypoxiaâinduciblefactorâ1αcan pages 1-2, li2024ftodeficiencyin pages 2-4) |
| Applications: BBB targeting, cancer delivery, sTfR biomarker | TfR1 remains a major receptor-mediated transcytosis target at the BBB; successful design principles emphasize monovalent/moderate-affinity binding, pH-dependent dissociation, recycling-biased epitopes, and controlled ligand density to avoid lysosomal trapping. Cancer implementations include transferrin- or anti-TfR1-based nanoparticles, liposomes, micelles, toxin conjugates, and protein-derived carbon dots. Soluble TfR (sTfR) serves as a clinical marker of tissue iron demand/erythropoiesis; in a 2023 HF cohort, a pragmatic cutoff of >1.63 mg/L identified patients with worse 6MWT and quality-of-life outcomes. | 2024 delivery reviews, 2024 nanoparticle/cell-targeting study, 2023 prospective human heart-failure cohort with regression analyses and figure/table support. | Guides translational use of TFRC in brain drug delivery and tumor targeting, while highlighting biomarker utility of sTfR and the lack of universally standardized cutoffs. | (li2024pathophysiologicalaspectsof pages 8-9, li2024pathophysiologicalaspectsof pages 9-10, strickland2024cancercelltargeting pages 1-2, shen2025targetingtransferrinreceptor pages 6-8, rasjimenez2023solubletransferrinreceptor pages 1-2, rasjimenez2023solubletransferrinreceptor pages 5-7, rasjimenez2023solubletransferrinreceptor media 424abe75) |
Table: This table condenses the most important TFRC/TfR1 findings for functional annotation, recent mechanistic advances, and translational relevance. It is useful as a quick-reference summary linking core biology to 2024 immune and ferroptosis studies and current application areas.
Limitations of this tool-based synthesis
- The UniProt note that TFRC âbelongs to the peptidase M28 family / M28B subfamilyâ and detailed domain architecture were not directly evidenced in the retrieved full-text excerpts; the functional annotation here is therefore grounded in contemporary literature describing TfR1 biology and clinically validated phenotypes rather than domain-family claims.
- Evidence for the biochemical identity of the sheddase(s) that generate sTfR (e.g., specific proteases such as ADAM family members) was not captured in the curated evidence snippets used above; the report therefore states sTfR as a proteolytically released form without assigning a specific protease.
Key URLs (with publication dates)
- Haqqani AS et al. Frontiers in Drug Delivery (Mar 2024): https://doi.org/10.3389/fddev.2024.1360302 (haqqani2024receptormediatedtranscytosisfor pages 2-3)
- Li C et al. Frontiers in Pharmacology (Mar 2024): https://doi.org/10.3389/fphar.2024.1342181 (li2024pathophysiologicalaspectsof pages 5-6, li2024pathophysiologicalaspectsof pages 8-9)
- Aba Ă et al. Journal of Clinical Immunology (Jan 2024): https://doi.org/10.1007/s10875-024-01658-0 (aba2024anovelhomozygous pages 4-5)
- Li R et al. Nature Communications (Jun 2024): https://doi.org/10.1038/s41467-024-49202-3 (li2024ftodeficiencyin pages 1-2)
- Zhu H et al. J Exp Clin Cancer Res (Aug 2024): https://doi.org/10.1186/s13046-024-03169-7 (zhu2024cct3actn4tfrcaxisprotects pages 1-2)
- Yu X et al. FASEB Journal (Aug 2024): https://doi.org/10.1096/fj.202401119r (yu2024hypoxiaâinduciblefactorâ1αcan pages 1-2)
- Ras-Jiménez MM et al. Journal of Personalized Medicine (Aug 2023): https://doi.org/10.3390/jpm13081282 (rasjimenez2023solubletransferrinreceptor pages 1-2)
- Strickland S et al. ACS Omega (Jan 2024): https://doi.org/10.1021/acsomega.3c07744 (strickland2024cancercelltargeting pages 1-2)
- Bu X & Wang L. International Journal of Molecular Medicine (Dec 2024): https://doi.org/10.3892/ijmm.2024.5480 (bu2024ironmetabolismand pages 4-5)
References
-
(haqqani2024receptormediatedtranscytosisfor pages 2-3): Arsalan S. Haqqani, Kasandra BĂ©langer, and Danica B. Stanimirovic. Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Frontiers in Drug Delivery, Mar 2024. URL: https://doi.org/10.3389/fddev.2024.1360302, doi:10.3389/fddev.2024.1360302. This article has 123 citations.
-
(li2024pathophysiologicalaspectsof pages 5-6): Chang Li, Liya Zhou, and Xunzhe Yin. Pathophysiological aspects of transferrin-a potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases. Frontiers in Pharmacology, Mar 2024. URL: https://doi.org/10.3389/fphar.2024.1342181, doi:10.3389/fphar.2024.1342181. This article has 33 citations.
-
(aba2024anovelhomozygous pages 1-2): Ămran Aba, Ä°brahim Cemal Maslak, Canberk Ä°pĆir, Damla Pehlivan, Nicholas I. Warnock, Damon J. Tumes, Gökhan Cildir, and Baran Erman. A novel homozygous germline mutation in transferrin receptor 1 (tfr1) leads to combined immunodeficiency and provides new insights into iron-immunity axis. Journal of Clinical Immunology, Jan 2024. URL: https://doi.org/10.1007/s10875-024-01658-0, doi:10.1007/s10875-024-01658-0. This article has 16 citations and is from a domain leading peer-reviewed journal.
-
(aba2024anovelhomozygous pages 4-5): Ămran Aba, Ä°brahim Cemal Maslak, Canberk Ä°pĆir, Damla Pehlivan, Nicholas I. Warnock, Damon J. Tumes, Gökhan Cildir, and Baran Erman. A novel homozygous germline mutation in transferrin receptor 1 (tfr1) leads to combined immunodeficiency and provides new insights into iron-immunity axis. Journal of Clinical Immunology, Jan 2024. URL: https://doi.org/10.1007/s10875-024-01658-0, doi:10.1007/s10875-024-01658-0. This article has 16 citations and is from a domain leading peer-reviewed journal.
-
(polizzi2026recentadvancesin pages 10-11): Alessandro Polizzi. Recent advances in research on iron metabolism, ferritin, and hepcidin. International Journal of Molecular Sciences, 27(2):906, Jan 2026. URL: https://doi.org/10.3390/ijms27020906, doi:10.3390/ijms27020906. This article has 2 citations.
-
(aba2024anovelhomozygous pages 9-12): Ămran Aba, Ä°brahim Cemal Maslak, Canberk Ä°pĆir, Damla Pehlivan, Nicholas I. Warnock, Damon J. Tumes, Gökhan Cildir, and Baran Erman. A novel homozygous germline mutation in transferrin receptor 1 (tfr1) leads to combined immunodeficiency and provides new insights into iron-immunity axis. Journal of Clinical Immunology, Jan 2024. URL: https://doi.org/10.1007/s10875-024-01658-0, doi:10.1007/s10875-024-01658-0. This article has 16 citations and is from a domain leading peer-reviewed journal.
-
(li2024ftodeficiencyin pages 1-2): Rong Li, Xijing Yan, Cuicui Xiao, Tingting Wang, Xuejiao Li, Zhongying Hu, Jinliang Liang, Jiebin Zhang, Jianye Cai, Xin Sui, Qiuli Liu, Manli Wu, Jiaqi Xiao, Haitian Chen, Yasong Liu, Chenhao Jiang, Guoshi Lv, Gui-huo Chen, Yingcai Zhang, Jia Yao, Jun Zheng, and Yang Yang. Fto deficiency in older livers exacerbates ferroptosis during ischaemia/reperfusion injury by upregulating acsl4 and tfrc. Nature Communications, Jun 2024. URL: https://doi.org/10.1038/s41467-024-49202-3, doi:10.1038/s41467-024-49202-3. This article has 84 citations and is from a highest quality peer-reviewed journal.
-
(li2024ftodeficiencyin pages 2-4): Rong Li, Xijing Yan, Cuicui Xiao, Tingting Wang, Xuejiao Li, Zhongying Hu, Jinliang Liang, Jiebin Zhang, Jianye Cai, Xin Sui, Qiuli Liu, Manli Wu, Jiaqi Xiao, Haitian Chen, Yasong Liu, Chenhao Jiang, Guoshi Lv, Gui-huo Chen, Yingcai Zhang, Jia Yao, Jun Zheng, and Yang Yang. Fto deficiency in older livers exacerbates ferroptosis during ischaemia/reperfusion injury by upregulating acsl4 and tfrc. Nature Communications, Jun 2024. URL: https://doi.org/10.1038/s41467-024-49202-3, doi:10.1038/s41467-024-49202-3. This article has 84 citations and is from a highest quality peer-reviewed journal.
-
(zhu2024cct3actn4tfrcaxisprotects pages 1-2): Huihui Zhu, Qiuhong Liu, Qinna Meng, Lingjian Zhang, Siwei Ju, Jiaheng Lang, Danhua Zhu, Yongxia Chen, Nadire Aishan, Xiaoxi Ouyang, Sainan Zhang, Lidan Jin, Lanlan Xiao, Linbo Wang, Lanjuan Li, and Feiyang Ji. Cct3/actn4/tfrc axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis. Journal of Experimental & Clinical Cancer Research : CR, Aug 2024. URL: https://doi.org/10.1186/s13046-024-03169-7, doi:10.1186/s13046-024-03169-7. This article has 29 citations.
-
(yu2024hypoxiaâinduciblefactorâ1αcan pages 1-2): Xiaojie Yu, Qingqun Guo, Haojie Zhang, Xiaohong Wang, Yong Han, and Zhenlin Yang. Hypoxiaâinducible factorâ1α can reverse the adriamycin resistance of breast cancer adjuvant chemotherapy by upregulating transferrin receptor and activating ferroptosis. The FASEB Journal, Aug 2024. URL: https://doi.org/10.1096/fj.202401119r, doi:10.1096/fj.202401119r. This article has 18 citations.
-
(shen2025targetingtransferrinreceptor pages 6-8): Xinai Shen, Huan Li, Beiyu Zhang, Yunan Li, and Zheying Zhu. Targeting transferrin receptor 1 for enhancing drug delivery through the bloodâbrain barrier for alzheimerâs disease. International Journal of Molecular Sciences, 26:9793, Oct 2025. URL: https://doi.org/10.3390/ijms26199793, doi:10.3390/ijms26199793. This article has 18 citations.
-
(li2024pathophysiologicalaspectsof pages 8-9): Chang Li, Liya Zhou, and Xunzhe Yin. Pathophysiological aspects of transferrin-a potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases. Frontiers in Pharmacology, Mar 2024. URL: https://doi.org/10.3389/fphar.2024.1342181, doi:10.3389/fphar.2024.1342181. This article has 33 citations.
-
(li2024pathophysiologicalaspectsof pages 6-8): Chang Li, Liya Zhou, and Xunzhe Yin. Pathophysiological aspects of transferrin-a potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases. Frontiers in Pharmacology, Mar 2024. URL: https://doi.org/10.3389/fphar.2024.1342181, doi:10.3389/fphar.2024.1342181. This article has 33 citations.
-
(strickland2024cancercelltargeting pages 1-2): Sara Strickland, Mychele Jorns, Luke Fourroux, Lindsey Heyd, and Dimitri Pappas. Cancer cell targeting via selective transferrin receptor labeling using protein-derived carbon dots. ACS Omega, 9:2707-2718, Jan 2024. URL: https://doi.org/10.1021/acsomega.3c07744, doi:10.1021/acsomega.3c07744. This article has 23 citations and is from a peer-reviewed journal.
-
(rasjimenez2023solubletransferrinreceptor pages 3-5): Maria del Mar Ras-JimĂ©nez, RaĂșl Ramos-Polo, Josep Francesch Manzano, Miriam Corbella Santano, Herminio Morillas Climent, NĂșria Jose-BazĂĄn, Santiago JimĂ©nez-Marrero, Paloma Garcimartin Cerezo, Sergi Yun Viladomat, Pedro Moliner Borja, Blanca Torres CardĂșs, JosĂ© Maria VerdĂș-Rotellar, Carles Diez-LĂłpez, JosĂ© GonzĂĄlez-Costello, Elena GarcĂa-Romero, Fernando de Frutos Seminario, Laura Triguero-Llonch, Cristina Enjuanes Grau, Marta Tajes Orduña, and Josep Comin-Colet. Soluble transferrin receptor as iron deficiency biomarker: impact on exercise capacity in heart failure patients. Journal of Personalized Medicine, 13:1282, Aug 2023. URL: https://doi.org/10.3390/jpm13081282, doi:10.3390/jpm13081282. This article has 7 citations.
-
(rasjimenez2023solubletransferrinreceptor media 424abe75): Maria del Mar Ras-JimĂ©nez, RaĂșl Ramos-Polo, Josep Francesch Manzano, Miriam Corbella Santano, Herminio Morillas Climent, NĂșria Jose-BazĂĄn, Santiago JimĂ©nez-Marrero, Paloma Garcimartin Cerezo, Sergi Yun Viladomat, Pedro Moliner Borja, Blanca Torres CardĂșs, JosĂ© Maria VerdĂș-Rotellar, Carles Diez-LĂłpez, JosĂ© GonzĂĄlez-Costello, Elena GarcĂa-Romero, Fernando de Frutos Seminario, Laura Triguero-Llonch, Cristina Enjuanes Grau, Marta Tajes Orduña, and Josep Comin-Colet. Soluble transferrin receptor as iron deficiency biomarker: impact on exercise capacity in heart failure patients. Journal of Personalized Medicine, 13:1282, Aug 2023. URL: https://doi.org/10.3390/jpm13081282, doi:10.3390/jpm13081282. This article has 7 citations.
-
(rasjimenez2023solubletransferrinreceptor pages 1-2): Maria del Mar Ras-JimĂ©nez, RaĂșl Ramos-Polo, Josep Francesch Manzano, Miriam Corbella Santano, Herminio Morillas Climent, NĂșria Jose-BazĂĄn, Santiago JimĂ©nez-Marrero, Paloma Garcimartin Cerezo, Sergi Yun Viladomat, Pedro Moliner Borja, Blanca Torres CardĂșs, JosĂ© Maria VerdĂș-Rotellar, Carles Diez-LĂłpez, JosĂ© GonzĂĄlez-Costello, Elena GarcĂa-Romero, Fernando de Frutos Seminario, Laura Triguero-Llonch, Cristina Enjuanes Grau, Marta Tajes Orduña, and Josep Comin-Colet. Soluble transferrin receptor as iron deficiency biomarker: impact on exercise capacity in heart failure patients. Journal of Personalized Medicine, 13:1282, Aug 2023. URL: https://doi.org/10.3390/jpm13081282, doi:10.3390/jpm13081282. This article has 7 citations.
-
(rasjimenez2023solubletransferrinreceptor pages 5-7): Maria del Mar Ras-JimĂ©nez, RaĂșl Ramos-Polo, Josep Francesch Manzano, Miriam Corbella Santano, Herminio Morillas Climent, NĂșria Jose-BazĂĄn, Santiago JimĂ©nez-Marrero, Paloma Garcimartin Cerezo, Sergi Yun Viladomat, Pedro Moliner Borja, Blanca Torres CardĂșs, JosĂ© Maria VerdĂș-Rotellar, Carles Diez-LĂłpez, JosĂ© GonzĂĄlez-Costello, Elena GarcĂa-Romero, Fernando de Frutos Seminario, Laura Triguero-Llonch, Cristina Enjuanes Grau, Marta Tajes Orduña, and Josep Comin-Colet. Soluble transferrin receptor as iron deficiency biomarker: impact on exercise capacity in heart failure patients. Journal of Personalized Medicine, 13:1282, Aug 2023. URL: https://doi.org/10.3390/jpm13081282, doi:10.3390/jpm13081282. This article has 7 citations.
-
(rasjimenez2023solubletransferrinreceptor pages 2-3): Maria del Mar Ras-JimĂ©nez, RaĂșl Ramos-Polo, Josep Francesch Manzano, Miriam Corbella Santano, Herminio Morillas Climent, NĂșria Jose-BazĂĄn, Santiago JimĂ©nez-Marrero, Paloma Garcimartin Cerezo, Sergi Yun Viladomat, Pedro Moliner Borja, Blanca Torres CardĂșs, JosĂ© Maria VerdĂș-Rotellar, Carles Diez-LĂłpez, JosĂ© GonzĂĄlez-Costello, Elena GarcĂa-Romero, Fernando de Frutos Seminario, Laura Triguero-Llonch, Cristina Enjuanes Grau, Marta Tajes Orduña, and Josep Comin-Colet. Soluble transferrin receptor as iron deficiency biomarker: impact on exercise capacity in heart failure patients. Journal of Personalized Medicine, 13:1282, Aug 2023. URL: https://doi.org/10.3390/jpm13081282, doi:10.3390/jpm13081282. This article has 7 citations.
-
(shen2025targetingtransferrinreceptor pages 4-5): Xinai Shen, Huan Li, Beiyu Zhang, Yunan Li, and Zheying Zhu. Targeting transferrin receptor 1 for enhancing drug delivery through the bloodâbrain barrier for alzheimerâs disease. International Journal of Molecular Sciences, 26:9793, Oct 2025. URL: https://doi.org/10.3390/ijms26199793, doi:10.3390/ijms26199793. This article has 18 citations.
-
(aba2024anovelhomozygous pages 2-4): Ămran Aba, Ä°brahim Cemal Maslak, Canberk Ä°pĆir, Damla Pehlivan, Nicholas I. Warnock, Damon J. Tumes, Gökhan Cildir, and Baran Erman. A novel homozygous germline mutation in transferrin receptor 1 (tfr1) leads to combined immunodeficiency and provides new insights into iron-immunity axis. Journal of Clinical Immunology, Jan 2024. URL: https://doi.org/10.1007/s10875-024-01658-0, doi:10.1007/s10875-024-01658-0. This article has 16 citations and is from a domain leading peer-reviewed journal.
-
(li2024pathophysiologicalaspectsof pages 9-10): Chang Li, Liya Zhou, and Xunzhe Yin. Pathophysiological aspects of transferrin-a potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases. Frontiers in Pharmacology, Mar 2024. URL: https://doi.org/10.3389/fphar.2024.1342181, doi:10.3389/fphar.2024.1342181. This article has 33 citations.
-
(bu2024ironmetabolismand pages 4-5): Xiaorui Bu and Lufang Wang. Iron metabolism and the tumor microenvironment: a new perspective on cancer intervention and therapy (review). International Journal of Molecular Medicine, Dec 2024. URL: https://doi.org/10.3892/ijmm.2024.5480, doi:10.3892/ijmm.2024.5480. This article has 38 citations and is from a peer-reviewed journal.
Artifacts
Citations
- haqqani2024receptormediatedtranscytosisfor pages 2-3
- li2024pathophysiologicalaspectsof pages 5-6
- polizzi2026recentadvancesin pages 10-11
- aba2024anovelhomozygous pages 4-5
- shen2025targetingtransferrinreceptor pages 6-8
- strickland2024cancercelltargeting pages 1-2
- rasjimenez2023solubletransferrinreceptor pages 1-2
- rasjimenez2023solubletransferrinreceptor pages 5-7
- li2024ftodeficiencyin pages 1-2
- bu2024ironmetabolismand pages 4-5
- aba2024anovelhomozygous pages 1-2
- aba2024anovelhomozygous pages 9-12
- li2024ftodeficiencyin pages 2-4
- li2024pathophysiologicalaspectsof pages 8-9
- li2024pathophysiologicalaspectsof pages 6-8
- rasjimenez2023solubletransferrinreceptor pages 3-5
- rasjimenez2023solubletransferrinreceptor pages 2-3
- shen2025targetingtransferrinreceptor pages 4-5
- aba2024anovelhomozygous pages 2-4
- li2024pathophysiologicalaspectsof pages 9-10
- https://doi.org/10.3389/fddev.2024.1360302
- https://doi.org/10.3389/fphar.2024.1342181
- https://doi.org/10.1007/s10875-024-01658-0
- https://doi.org/10.1038/s41467-024-49202-3
- https://doi.org/10.1186/s13046-024-03169-7
- https://doi.org/10.1096/fj.202401119r
- https://doi.org/10.3390/jpm13081282
- https://doi.org/10.1021/acsomega.3c07744
- https://doi.org/10.3892/ijmm.2024.5480
- https://doi.org/10.3389/fddev.2024.1360302,
- https://doi.org/10.3389/fphar.2024.1342181,
- https://doi.org/10.1007/s10875-024-01658-0,
- https://doi.org/10.3390/ijms27020906,
- https://doi.org/10.1038/s41467-024-49202-3,
- https://doi.org/10.1186/s13046-024-03169-7,
- https://doi.org/10.1096/fj.202401119r,
- https://doi.org/10.3390/ijms26199793,
- https://doi.org/10.1021/acsomega.3c07744,
- https://doi.org/10.3390/jpm13081282,
- https://doi.org/10.3892/ijmm.2024.5480,
Perplexity
(TFRC-deep-research-perplexity.md)
Perplexity
(TFRC-deep-research-perplexity.md)Transferrin Receptor Protein 1 (TFRC): A Comprehensive Analysis of Molecular Structure, Function, and Biological Significance
Executive Summary
Transferrin receptor protein 1 (TfR1), also designated as cluster of differentiation 71 (CD71), represents one of the most extensively characterized iron transport proteins in humans, encoded by the TFRC gene located on chromosome 3[1][3]. As a cell surface glycoprotein expressed on virtually all nucleated cells, TfR1 functions as the primary gateway for cellular iron acquisition through receptor-mediated endocytosis of iron-bound transferrin molecules[10][32]. The protein's significance extends well beyond basic iron homeostasis, encompassing critical roles in erythropoiesis, proliferation of rapidly dividing cells, and emerging therapeutic applications in cancer treatment and drug delivery to the brain. Understanding TfR1's molecular mechanisms, regulatory pathways, and biological contexts illuminates fundamental principles of cellular nutrient acquisition and reveals potential vulnerabilities that cancer cells exploit to support their elevated metabolic demands. This comprehensive report synthesizes current knowledge regarding TfR1's structure, function, intracellular trafficking, regulation, and clinical relevance, providing a detailed mechanistic foundation for understanding how this receptor orchestrates iron import and influences cellular physiology across diverse biological contexts.
Molecular Structure and Protein Architecture
Transmembrane Organization and Structural Domains
TfR1 is a transmembrane glycoprotein composed fundamentally of two disulfide-linked monomers, each approximately 90 kilodaltons in size, creating a functional homodimer at the cell surface[1][2][27]. The protein architecture comprises a single transmembrane domain with an extracellular ectodomain containing the iron and transferrin binding regions, a membrane-proximal region, and a relatively short cytoplasmic tail of approximately 67 amino acids[1][47]. The two polypeptide chains are covalently linked by disulfide bonds at residues 89 and 98, positioned immediately extracellular to the transmembrane domain, which provides structural stability to the dimeric complex[15]. Notably, crystallographic studies have revealed that the disulfide-linked dimeric structure, while providing stability, is not absolutely essential for the protein's functional activity, as non-covalently linked dimers retain substantial iron transport capacity[27].
The three-dimensional structure of the TfR1 ectodomain reveals three distinct functional domains arranged within each monomeric subunit[49][52]. One domain exhibits striking structural similarity to carboxypeptidases and aminopeptidases, belonging to the M28 family of zinc-dependent proteases, though TfR1 itself is catalytically inactive as a peptidase[43][49]. This protease-like domain participates critically in both transferrin binding and in stabilizing the conformational changes necessary for iron release from transferrin within acidic endosomal compartments[49][60]. The remaining domains include an apical domain and a helical domain, each contributing essential interactions with ligand molecules and mediating conformational changes during the iron transport cycle[60]. The structural organization positions these domains to facilitate binding of iron-laden transferrin at physiological pH on the cell surface while simultaneously preparing the receptor for the conformational rearrangements triggered by endosomal acidification[49][52].
Post-Translational Modifications and Chemical Modifications
TfR1 undergoes multiple post-translational modifications that influence its localization, stability, and functional activity. Each monomeric chain is extensively glycosylated, with N-linked carbohydrate moieties contributing to protein stability, trafficking, and potentially immune recognition[1][2]. Additionally, the protein is palmitoylated at the inner membrane surface, a lipid modification occurring on intracellular cysteine residues that enhances membrane association and may influence lateral mobility within the plasma membrane[1][26]. The cytoplasmic domain contains a unique phosphorylation site at serine residue 24, though surprisingly, phosphorylation at this site does not appear critical for the protein's endocytic function or basolateral sorting in polarized cells[58]. This observation suggests that while phosphorylation occurs in response to kinase activity, it may not constitute an essential regulatory mechanism for basal iron transport function, though it might modulate responses to specific cellular signals or growth factors.
Iron Transport Function and Cellular Iron Acquisition
Molecular Mechanism of Transferrin Binding and Internalization
The primary physiological function of TfR1 involves binding iron-loaded transferrin (holo-transferrin) at the cell surface and mediating its entry into cells through clathrin-dependent endocytosis[2][7][10]. Iron in plasma exists in a highly restricted form, primarily bound to transferrin, an 85-kilodalton transport protein carrying up to two ferric iron (FeÂłâș) atoms in two distinct binding sites designated the C-terminal lobe and N-terminal lobe[2][15]. TfR1 exhibits striking selectivity for diferric transferrin over iron-free apotransferrin at neutral pH, creating a mechanism that ensures cells preferentially import iron-loaded molecules while generally excluding iron-depleted transferrin from cellular uptake[15][57]. The C-lobe and N-lobe of transferrin each interact with distinct regions of the TfR1 ectodomain, with the C-lobe engaging the helical domain of the receptor while the N-lobe contacts the stalk region[57].
Upon holo-transferrin binding, the transferrin-TfR1 complex undergoes rapid clustering within specialized plasma membrane invaginations called coated pits, which are lined with the clathrin scaffolding protein[1][7]. The formation of these coated pits requires multiple machinery components, including the clathrin complex itself, adaptor proteins, and dynamin, a GTPase essential for membrane scission[7]. Within these coated structures, phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)Pâ) plays a critical regulatory role, as inactivation of this phospholipid directly reduces transferrin internalization and increases surface levels of TfR1, demonstrating the importance of lipid composition in regulating this entry pathway[7]. The internalized transferrin-receptor complex is transported in clathrin-coated vesicles that rapidly lose their clathrin coats and fuse with early endosomal compartments within minutes of internalization[7][9].
Iron Release and Endosomal Sorting
Once internalized into early endosomes, a critical pH-dependent conformational change occurs that dramatically alters the transferrin-TfR1 interaction and enables iron release[5][15][57]. The early endosomal compartment maintains a pH of approximately 5.0-6.0, maintained by vacuolar ATPase proton pumps, which creates an acidic microenvironment promoting protonation of histidine residues within both transferrin and the receptor[2][5]. This acidification triggers dramatic conformational changes in the transferrin molecule, particularly affecting the iron binding sites and the interaction interfaces between transferrin and its receptor[57][60]. Specifically, protonation of His349 in the C-terminal lobe at acidic pH converts a hydrophobic interaction with Phe760 of the TfR into a stronger cation-Ï interaction or salt bridge with Asp757, causing a conformational change that destabilizes the iron binding cleft in the C-lobe[60]. Simultaneously, the N-lobe undergoes movement of its PRKP loop that disrupts the N2 subdomain's interaction with the receptor, allowing the iron binding cleft to open and release the iron atom[60].
Critically, the transferrin receptor itself undergoes ligand-dependent conformational changes that actively promote iron release from transferrin at acidic pH[5][60]. The binding of iron-loaded transferrin causes rotation at the TfR1 dimer interface, bringing four critical histidine residues (His475 in each protease-like domain and His684 in each helical domain) into proximity[60]. These conformational changes at the dimer interface prime the receptor to undergo additional pH-induced movements when exposed to endosomal acidification, directly facilitating the conformational changes in transferrin that enable iron dissociation[60]. This active role of the receptor in stimulating iron release represents a sophisticated mechanism ensuring efficient iron delivery into the cell[5]. Additionally, within endosomes, the ferric iron (FeÂłâș) released from transferrin is rapidly reduced to ferrous iron (FeÂČâș) by metalloproteases, notably STEAP3, a process essential for subsequent iron export from the endosome[2].
Iron Export and Intracellular Distribution
Once iron is released from transferrin within acidic endosomes, the ferrous iron (FeÂČâș) must be transported across the endosomal membrane into the cytoplasm through the action of divalent metal transporter 1 (DMT1, also called SLC11A2)[2][14]. DMT1 functions as a proton-coupled iron transporter, with the acidic endosomal environment providing the proton gradient necessary to drive iron uptake across the endosomal membrane[2][14]. Once in the cytoplasm, iron faces three potential metabolic fates depending on cellular needs[2]. Iron may be immediately incorporated into ferritin, a 24-subunit iron storage protein that safely sequesters iron in mineral form as ferrihydrite, protecting against the generation of reactive oxygen species through Fenton chemistry[2][14]. Alternatively, iron may be transported to mitochondria for incorporation into heme groups and iron-sulfur clusters, essential cofactors in the electron transport chain and numerous metabolic enzymes[2][40]. Finally, iron may be exported back into the extracellular environment through ferroportin (SLC40A1), the only known cellular iron exporter, allowing iron redistribution to other tissues[2][14].
The export of iron through ferroportin is tightly regulated by hepcidin, a circulating peptide hormone produced by hepatocytes that binds ferroportin and triggers its ubiquitin-mediated degradation, thereby preventing iron export and causing cellular iron retention[14]. This systemic hormone represents the critical control point for whole-body iron homeostasis, linking iron sensing in the liver to the regulation of iron absorption in the intestine and iron recycling in macrophages[14]. Understanding this regulatory axis proves essential for comprehending both normal iron metabolism and iron overload disorders.
Intracellular Trafficking Pathway and Receptor Recycling
Clathrin-Mediated Endocytosis and Early Endosomal Sorting
The internalization of transferrin receptor and its ligand occurs through well-characterized clathrin-mediated endocytosis, involving recruitment of the receptor into coated pits through interactions with adaptor protein complexes[7][49]. The AP2 adaptor complex, comprising four subunits (α, ÎČ, ÎŒ, and Ï), binds directly to a critical YXRF internalization motif (where Y is tyrosine, X is any amino acid, R is arginine, and F is phenylalanine) located within the cytoplasmic tail of TfR1[58]. This motif appears to form a tight turn structure that is specifically recognized by adaptor proteins, ensuring efficient clustering of the receptor into coated pits[58]. Once internalized into clathrin-coated vesicles, the vesicles rapidly lose their clathrin coat through the action of uncoating proteins, exposing the underlying transport vesicle to fusion machinery[7].
The early endosomal compartment represents a highly dynamic sorting station where cargo molecules are distributed to distinct cellular destinations based on their biochemical properties[7][9]. Early endosomes exist in two functionally distinct populationsâdynamic early endosomes that mature through transitional stages, and static early endosomes that remain relatively stable[7]. The sorting of transferrin at the cell surface appears to begin immediately upon binding and receptor clustering, with early segregation occurring through TIRF (Total Internal Reflection Fluorescence) microscopy-visualized mechanisms within 100-200 nanometers of the plasma membrane[7]. This pre-endosomal sorting suggests that the cell possesses mechanisms for distinguishing cargo molecules even before their entry into membrane-enclosed compartments, potentially through preferential inclusion in distinct lipid microdomains or through interactions with specific sorting proteins[7].
Recycling Endosome Trafficking and Plasma Membrane Return
Following iron release in early endosomes, both the transferrin receptor and iron-depleted transferrin (apotransferrin) must be recycled back to the cell surface to complete the iron transport cycle and to allow transferrin molecules to acquire new iron in the bloodstream[7][9]. This recycling process is mediated through recycling endosomes, specialized compartments enriched in the Rab11 GTPase, which functions as a crucial regulator of membrane trafficking from recycling endosomes back to the plasma membrane[7][59]. Real-time fluorescence microscopy studies have revealed that transferrin moves into tubular formations in both static and dynamic early endosomes before separating, with these vesicles then delivering transferrin to either the perinuclear recycling compartment or directly back to the plasma membrane[7]. The perinuclear recycling compartment, marked by Rab11 localization, represents a major hub for receptor sorting and redistribution[7][59].
Multiple small GTPases of the Rab family regulate distinct steps of the transferrin recycling pathway, with Rab4, localized primarily in early endosomes, mediating rapid recycling of some transferrin receptor molecules directly from early endosomes to the plasma membrane[7]. Overexpression of Rab4 causes accumulation of transferrin in tubular structures and vesicles directed toward the recycling compartment, suggesting that Rab4 modulates the velocity and efficiency of recycling[7]. The GEF Grab (guanine nucleotide exchange factor for Rab8) has emerged as another critical regulator of transferrin receptor recycling specifically in erythroid cells, with GRAB knockdown reducing transferrin-bound iron uptake and causing hypochromic-microcytic anemia in mouse models[37]. The exocyst, a multiprotein complex involved in tethering recycling vesicles to the plasma membrane, appears to be recruited by active Rab8 in a Grab-dependent manner, providing a molecular link between Rab GTPase activation and vesicle fusion[37].
Sorting Between Recycling and Lysosomal Degradation
While TfR1 is predominantly recycled back to the plasma membrane to maintain high iron import capacity, constitutive degradation of the receptor also occurs through a specialized Rab12-dependent pathway[59]. Small GTPase Rab12 and its upstream activator Dennd3 regulate the trafficking of TfR1 from recycling endosomes to lysosomes, with Rab12 activation promoting TfR1 degradation[59]. This constitutive degradation pathway appears distinct from conventional endocytic degradation through late endosomes and multivesicular bodies, instead operating through direct trafficking from recycling endosomes to lysosomes[59]. The physiological significance of this basal degradation pathway remains unclear but may provide a mechanism for modulating TfR1 levels independent of iron-responsive transcriptional regulation[59].
Additionally, under conditions of iron excess, TfR1 undergoes iron-induced selective degradation through lysosomal pathways, providing a mechanism to reduce iron uptake capacity when intracellular iron levels become elevated[59]. This iron-regulated degradation complements the transcriptional downregulation of TfR1 mediated through iron-responsive elements, creating multiple levels of control over iron import capacity[59]. Importantly, recent studies employing cryo-electron microscopy have revealed structural details of how the transferrin receptor interacts with its ligands in the endosomal environment, showing that the apical domain of TfR1 mediates binding to heavy-chain ferritin through a distinct set of epitopes compared to those used for transferrin binding, allowing differential regulation of iron acquisition from these two sources[22].
Regulation of Transferrin Receptor Expression
Iron-Responsive Element Regulation
The cellular abundance of transferrin receptor is tightly regulated by iron status through a sophisticated post-transcriptional mechanism involving iron-responsive elements (IREs) and iron regulatory proteins (IRPs)[31][34]. The 3âČ untranslated region (3âČ UTR) of TFRC mRNA contains five IREs, which are short conserved stem-loop structures recognized by two functionally similar iron regulatory proteins, IRP1 and IRP2[31][34]. Under conditions of low intracellular iron, these IRPs bind avidly to the TFRC IREs, stabilizing the mRNA and preventing its degradation[31][34]. The protective effect of IRP binding appears mediated through blocking access of endonucleases to the unstable regions within the 3âČ UTR, as mutagenesis studies have identified multiple non-IRE stem-loops contributing minimally to mRNA instability but enhancing instability when IRP protection is lost[31].
When intracellular iron levels rise, IRP1 undergoes an iron-sulfur cluster (Fe-S) assembly that converts it into an aconitase-like conformation unsuitable for IRE binding, causing its release from the TFRC mRNA and allowing the mRNA to be rapidly degraded[34]. IRP2, by contrast, is ubiquitinated and proteasomally degraded under iron-replete conditions[34]. This iron-sensing mechanism achieves remarkable specificity through direct iron binding to the IRE itself, which induces conformational changes favoring eIF4F (eukaryotic Initiation Factor 4F) binding over IRP binding, creating a conformational switch that responds to iron status[14][34]. The regulatory response appears graded rather than switch-like, with progressive loss of IRP protection occurring as iron levels increase, allowing cells to fine-tune TfR1 expression in response to cellular iron demands[31].
Transcriptional and Signal-Responsive Regulation
Beyond the iron-responsive post-transcriptional regulation, TfR1 expression is modulated by multiple transcriptional and signaling pathways responding to cellular growth, differentiation signals, and metabolic states[1][2]. Growth factors including insulin and insulin-like growth factors upregulate TfR1 expression, reflecting increased iron demands of proliferating cells[2]. Erythropoietin (EPO), a key regulator of red blood cell production, strongly induces TfR1 expression in erythroid progenitors, enabling the massive iron uptake necessary for hemoglobin synthesis during erythropoiesis[40]. The transcriptional upregulation of TFRC during erythroid differentiation occurs through multiple pathways, including the GATA1 transcription factor crucial for erythroid-specific gene expression, demonstrating integration of iron metabolism control with the physiological demands of hematopoiesis[40].
Interestingly, TFRC expression is also regulated through alternative splicing mechanisms responsive to iron status and cellular context, with evidence suggesting that the transferrin receptor itself possesses RNA-binding protein properties influencing splicing patterns of genes involved in iron metabolism, DNA repair, and translation[36]. This newly appreciated function of TfR1 as an RNA-binding protein adds an additional layer of complexity to iron metabolism regulation, suggesting that TfR1 may coordinate iron uptake with cellular processes dependent on iron availability at the transcriptional level[36].
Protein Interactions and Functional Partnerships
Interaction with HFE and Regulation of Hepcidin Expression
A critical interaction occurs between TfR1 and HFE (hemochromatosis protein), the protein mutated in hereditary hemochromatosis type 1[20][23]. HFE interacts with TfR1 through the α1 and α2 domains of HFE and functions as a regulatory cofactor that modulates the iron-sensing properties of the transferrin receptor system[20][23]. The HFE-TfR1 complex appears to interact with TfR2 (transferrin receptor 2), creating a supramolecular complex involved in iron sensing and signaling to regulate hepcidin expression, the master hormone controlling systemic iron homeostasis[20]. The TfR2/HFE complex detects iron-loaded transferrin and triggers activation of BMP-SMAD signaling pathways that enhance hepcidin transcription in hepatocytes[20]. Specifically, the iron-bound transferrin-TfR2-HFE complex mediates conformational changes that activate downstream signaling, ensuring that increased iron availability triggers increased hepcidin production to limit further iron absorption[20].
Importantly, disruption of the HFE-TfR1 interaction alone does not impair hepcidin regulation, suggesting that HFE sequestration from TfR1 allows its interaction with TfR2, which appears to be the critical complex for hepcidin regulation[20]. This model proposes that TfR1 competes with TfR2 for HFE binding under low holo-transferrin conditions, but when iron-loaded transferrin concentrations increase, the holo-transferrin-TfR2-HFE complex forms and activates hepcidin transcription[20]. Evidence supporting this model includes observations that in TfR1 mutant mice lacking functional TfR1, higher levels of hepcidin mRNA accumulate, consistent with increased availability of HFE to bind TfR2[20]. This elegant regulatory mechanism demonstrates how TfR1's role extends beyond simple iron uptake to encompass systemic iron homeostasis through protein-protein interactions controlling hormonal signaling[20].
Ferritin Binding and Alternative Iron Acquisition Pathways
Beyond transferrin, TfR1 binds heavy-chain ferritin (H-Ft), providing an alternative source of bioavailable iron for cells[19][22]. Ferritin, a spherical 24-subunit iron storage protein composed of heavy-chain (FHC) and light-chain (FLC) subunits, circulates in plasma at low concentrations and can be internalized by cells expressing TfR1[19][22]. The binding of ferritin to TfR1 occurs through distinct epitopes compared to those used for transferrin binding, with structural studies revealing that specific residues in the ferritin BC-loop (particularly Y211 and N-terminal residues of the A helix including Q14, D15, and R22) are critical for receptor recognition[22]. Notably, ferritin composed entirely of light chains does not bind TfR1, indicating that heavy-chain subunits provide the essential binding determinants[19][22]. Upon binding and internalization through TfR1-mediated endocytosis, ferritin enters both endosomal and lysosomal compartments where acidification and proteolysis release stored iron[19].
The functional significance of ferritin-TfR1 interaction becomes particularly apparent in erythroid precursors, where ferritin uptake via TfR1 can provide sufficient iron for hemoglobin synthesis in the absence of transferrin, demonstrating functional redundancy in iron acquisition pathways[19]. This dual-receptor function suggests that ferritin and transferrin may serve complementary roles in coordinating iron processing and utilization, potentially allowing cells to respond flexibly to varying iron bioavailability in different physiological contexts[19][22]. The shared use of TfR1 for both transferrin and ferritin uptake raises interesting questions about how endosomal iron metabolism differs between these two pathways and whether ferritin-derived iron might supply specific pools of iron within the cell[19].
Cellular and Tissue Distribution
Expression Patterns in Normal Tissues and Cell Types
TfR1 exhibits a remarkably broad tissue distribution, reflecting the fundamental importance of iron for virtually all nucleated cells[13][16]. Expression is particularly abundant in tissues with high metabolic rates or rapid cell proliferation, including bone marrow, placenta, and rapidly proliferating epithelial tissues[13][16]. Within normal bone marrow, TfR1 is expressed predominantly on erythroid precursor cells of all maturation stages, with expression being essentially absent from mature erythrocytes[1][2][40]. This developmental pattern of expression makes physiological sense, as mature red blood cells have lost their nuclei and cannot synthesize new hemoglobin, eliminating their requirement for iron import[40]. In contrast, erythroid precursor cells express extremely high levels of TfR1 to satisfy the enormous iron demands of hemoglobin synthesis, with approximately 80% of total cellular iron utilization occurring in erythroid precursors for hemoglobin production, and consequently, approximately 80% of total TfR1 is expressed on erythroid cells[15][40].
Beyond erythropoiesis, TfR1 is expressed on hepatocytes, Kupffer cells (tissue macrophages of the liver), endocrine pancreas cells, basal epidermis, testicular tissue, and pituitary cells in normal tissues[13]. This distribution reflects the iron requirements of different cell types for essential enzymatic functions and metabolic processes[13]. The restricted pattern of expression in normal tissues contrasts sharply with its widespread upregulation in malignant neoplasms, where rapidly dividing cancer cells dramatically increase TfR1 expression to meet escalated iron demands for ribonucleotide reductase and other iron-dependent biosynthetic enzymes required for DNA synthesis and cell proliferation[13][39].
Expression in Erythropoiesis and Hemoglobin Synthesis
Erythropoiesis represents the physiological context in which TfR1 achieves its highest expression levels and most critical functional importance[40]. During differentiation of erythroid progenitors stimulated by erythropoietin (EPO), cells progressively increase TfR1 surface levels, enabling them to import the massive quantities of iron required for hemoglobin synthesis[40]. The process of hemoglobin production demands approximately 30 million iron atoms per second in an adult human, highlighting the extraordinary iron-handling capacity that must be maintained by the erythroid compartment[40]. Recent discoveries have identified Grab, a guanine nucleotide exchange factor for Rab8, as a critical erythroid-specific regulator of TfR1 recycling to the plasma membrane[37]. Polymorphisms in GRAB and RAB8 genes associate with variations in mean corpuscular hemoglobinization of red blood cells, indicating that genetic variation in recycling machinery influences iron delivery efficiency and ultimately hemoglobin accumulation[37].
The Grab-Rab8 axis appears to function by recruiting the exocyst to recycling endosomes in an iron-demand-responsive manner, controlling the rate at which TfR1 is returned to the plasma membrane to import additional iron[37]. In Grab-deficient cells, TfR1 fails to recycle efficiently, accumulating in intracellular compartments and eventually being diverted to lysosomes for degradation, resulting in decreased cellular iron uptake and reduced hemoglobin synthesis[37]. These findings suggest that erythroid-specific recycling machinery provides a regulatory point for modulating iron uptake capacity in response to the differentiation stage and hemoglobin synthesis requirements of developing red blood cells[37].
Specialized Functions and Pathological Roles
Blood-Brain Barrier Transcytosis and Central Nervous System Iron Delivery
The blood-brain barrier (BBB) presents a formidable obstacle to drug delivery to the central nervous system, restricting passage of most large molecules and permitting only small, lipophilic compounds to cross the endothelial monolayer forming this barrier[24]. However, TfR1 is highly expressed on brain endothelial cells of the BBB, where it mediates transcytosis of transferrin-bound iron from systemic circulation into brain parenchyma, delivering this essential nutrient across an otherwise impermeable barrier[24]. Antibodies targeting TfR1, particularly anti-TfR1 monoclonal antibodies, have been engineered to exploit this physiological transcytotic pathway for drug delivery, with the antibodies being internalized at the luminal surface of brain endothelial cells and transcytosed to the abluminal surface, delivering attached therapeutic cargo to brain tissues[21][24].
The efficiency of transcytosis appears critically dependent on the binding affinity of anti-TfR1 antibodies to their epitope[21]. Paradoxically, high-affinity antibodies demonstrate reduced transcytosis efficiency, with antibodies showing affinities of 76 nanoMolar and 108 nanoMolar transporting more efficiently across the BBB than high-affinity 5 nanoMolar variants[21]. The mechanistic explanation for this counterintuitive finding involves antibody sorting and trafficking within endosomal compartmentsâhigh-affinity bivalent antibodies are preferentially directed toward late endosomes and lysosomes for degradation, whereas lower-affinity variants are preferentially sorted toward early endosomes, from which they can be efficiently recycled and exocytosed on the abluminal surface[21]. This sorting mechanism appears linked to alterations in endocytic recycling pathways triggered by different avidity states of antibody-receptor interactions, with monovalent antibodies showing particular efficiency in promoting transcytosis by favoring early endosomal sorting tubules[21].
Role in Cancer Cell Proliferation and Metabolic Support
TfR1 is dramatically overexpressed on the surfaces of malignant cells from multiple cancer types, including breast cancer, gliomas, ovarian cancer, lung cancer, hepatocellular carcinoma, and colon cancer, establishing it as a universal cancer biomarker[39][42]. Cancer cells upregulate TfR1 expression to meet escalated iron demands driven by rapid proliferation requiring DNA synthesis, the rate-limiting step of which depends on ribonucleotide reductase (RNR)âan iron-dependent enzyme synthesizing nucleotide precursors[39][42]. Iron serves as an essential cofactor for the R1 subunit of ribonucleotide reductase, which forms a critical tyrosyl radical on Tyr122 required for catalytic activity[39]. Additionally, iron-dependent proteins including electron transport chain components become increasingly critical in cancer cells supporting altered metabolic states, making iron availability a potential therapeutic vulnerability[42].
Studies demonstrating blocking of anti-TfR1 monoclonal antibodies inhibit cancer cell proliferation through iron deprivation represent proof-of-concept for TfR1-targeted therapeutic approaches[42]. Notably, anti-TfR1 antibodies inhibit growth of erythroleukemia and B-cell lymphoma cell lines with IC50 values as low as 0.1 micrograms per milliliter, with in vivo studies showing tumor regression in xenograft models through mechanisms involving both iron deprivation and antibody-dependent cellular cytotoxic effector functions[51]. Importantly, anti-TfR1 treatment additionally upregulates hypoxia-inducible factor-1 alpha (HIF-1α) through reduced iron availability for prolyl hydroxylase activity, potentially increasing tumor angiogenesis, suggesting that optimal therapeutic strategies might combine anti-TfR1 antibodies with agents targeting hypoxia pathways[42].
Recent evidence indicates that TfR1 expression correlates with poor overall survival in osteosarcoma patients, with TFRC knockdown in osteosarcoma cell lines significantly reducing proliferation, migration, and invasion abilities[39]. The mechanism involves decreased total intracellular iron content following TFRC knockdown, leading to reduced ribonucleotide reductase 2 (RRM2) expression and activity[39]. Remarkably, the reduction in osteosarcoma cell proliferation caused by TFRC knockdown can be reversed by supplementing cells with ferric ammonium citrate (FAC) or by overexpressing RRM2, directly demonstrating that TFRC-mediated iron uptake drives RRM2-dependent DNA synthesis supporting cancer cell proliferation[39].
Viral Exploitation of Transferrin Receptor for Cell Entry
Multiple viral pathogens have evolved to exploit TfR1 as a cellular entry receptor, exploiting the abundance of this protein on target cells and its constitutive endocytic trafficking to acidic compartments favorable for viral membrane fusion[50][53]. New World arenaviruses causing hemorrhagic fevers in humansâincluding Machupo, Guanarito, Junin, and Sabia virusesâutilize human TfR1 as their cellular receptor, with the viral entry glycoprotein (GP) binding directly and specifically to TfR1[53]. Expression of human TfR1 in hamster cell lines markedly enhances infection by pseudoviruses displaying New World arenavirus GPs, whereas cells lacking TfR1 show minimal infection[53]. Conversely, Old World arenaviruses such as Lassa virus do not utilize TfR1 but instead use α-dystroglycan as a cellular receptor, demonstrating specific viral adaptation to particular receptor systems[53].
The structural basis for TfR1-viral GP interaction involves specific epitopes on TfR1 that are recognized by viral glycoproteins with high affinity comparable to transferrin binding[53]. Critically, anti-TfR1 monoclonal antibodies efficiently inhibit replication of Machupo, Guanarito, Junin, and Sabia viruses but not Lassa virus, demonstrating the functional requirement for TfR1 in New World arenavirus infection[53]. Remarkably, iron status influences viral infection efficiency, with iron depletion enhancing infection of Junin and Machupo pseudoviruses but not affecting Lassa virus, suggesting that iron-dependent conformational changes of TfR1 may enhance viral GP binding[53]. This viral dependence on TfR1 reflects both the abundance of this receptor on target cells and the evolutionary optimization of viral entry mechanisms to exploit constitutive endocytic pathways that deliver viral particles to appropriate intracellular compartments for membrane fusion[50][53].
Role in Immune Dysfunction and Autoimmune Disease
Emerging research reveals that TfR1-mediated iron uptake plays unexpected roles in immune cell dysfunction and autoimmune diseases. In systemic lupus erythematosus (SLE), a prototypic autoimmune disease characterized by dysfunctional T cells, recent CRISPR screening identified TfR1 (CD71) as a critical factor specifically critical for T helper 17 cell (TH17) differentiation and inhibitory for induced regulatory T cells (iTregs)[54]. SLE-prone T cells display enhanced CD71 expression resulting from altered endosomal recycling, leading to increased intracellular iron accumulation[54]. This elevated iron uptake impairs mitochondrial function and mTORC1 signaling, skewing T cell differentiation toward pro-inflammatory TH17 and away from immunosuppressive iTregs[54]. Remarkably, anti-CD71 treatment reduces intracellular iron, inhibits TH17 differentiation, promotes IL-10 production by CD4 T cells, and reverses disease manifestations in SLE-prone mice[54]. Disease severity in SLE patients correlates directly with CD71 expression on TH17 cells, highlighting the pathogenic role of iron metabolism dysregulation in autoimmune dysfunction[54].
Clinical Applications and Diagnostic Utility
Soluble Transferrin Receptor as a Biomarker
TfR1 undergoes proteolytic cleavage at an Arg-Leu bond distal to the second disulfide bond linking the two monomers, releasing the soluble form of transferrin receptor (sTfR), a truncated protein lacking the transmembrane domain and consisting of 660 amino acids comprising the ectodomain[15][18]. This soluble form circulates in plasma at concentrations proportional to total cellular TfR1 abundance, making sTfR a valuable biomarker for iron metabolism status[15][18]. Approximately 80% of metabolic iron is incorporated into hemoglobin by erythroid precursors, and since most cellular TfR1 resides on erythroid cells, circulating sTfR concentration reflects erythroid precursor mass and erythropoiesis rate[15][40].
Circulating sTfR is particularly clinically useful for distinguishing iron deficiency from other causes of anemia or elevated ferritin levels[18]. Unlike ferritin, which functions as an acute-phase reactant elevated during inflammation, infection, malignancy, and chronic disease without indicating iron deficiency, sTfR is not influenced by inflammatory states[18]. Patients with iron deficiency show elevated sTfR levels as their erythroid precursor cells upregulate TfR1 to maximize iron capture from limited iron availability[18]. In contrast, patients with hypoplastic anemias (reduced erythropoiesis due to bone marrow failure) show low sTfR levels despite potentially low iron, allowing discrimination between iron deficiency and bone marrow failure[18]. Additionally, sTfR has been employed as a marker for erythropoietin (EPO) misuse by athletes, as EPO administration increases erythropoiesis and consequently sTfR levels, providing a physiological indicator of illicit EPO injection[4].
Immunohistochemical Applications
CD71 (TfR1) serves as a robust immunohistochemical marker for several tissue types and disease processes. In particular, CD71 is highly expressed on chorionic villous trophoblasts of the placenta, with CD71 immunostaining particularly useful for identifying villous structures in necrotic or autolytic specimens where other morphologic features become obscured[1][13]. Among hematopoietic cells, CD71 is expressed specifically by erythroid precursors within the normal bone marrow and spleen, with this restricted expression pattern allowing discrimination of erythroid lineage cells from other hematopoietic populations[1][2]. In combination with markers specific to more mature erythrocytes such as glycophorin A (recognized by the TER-119 antibody in mice), flow cytometry analysis can track erythroid differentiation and assess changes in erythropoiesis during disease or treatment[2]. The CD71-positive population in bone marrow encompasses early erythroid precursors (proerythroblasts and early normoblasts) that actively synthesize hemoglobin, providing a specific identification of erythropoietic activity[2].
Therapeutic Targeting and Drug Development
The prominent role of TfR1 in iron-dependent proliferation of cancer cells and its use by pathogenic viruses has spurred substantial drug development efforts targeting this receptor. Anti-TfR1 monoclonal antibodies represent the most advanced class of TfR1-targeting therapeutics, with multiple antibody formats being evaluated in clinical trials[51]. These antibodies block transferrin binding to TfR1, preventing iron-loaded transferrin internalization and causing iron starvation in target cells. Some anti-TfR1 antibodies show rapid internalization upon binding, making them suitable for delivery of attached therapeutic cargos into cells[51]. This property has enabled development of anti-TfR1 antibody-drug conjugates and fusion proteins combining anti-TfR1 antibodies with toxins, enzymes, or other therapeutic agents, allowing selective drug delivery to TfR1-expressing cancer cells[51].
InatherYs (now part of the InatherYs group), a biotechnology company in Ăvry, France, developed INA01, an anti-CD71 antibody candidate demonstrating efficacy in preclinical studies for treating two incurable orphan hematologic malignanciesâadult T cell leukemia (ATLL) caused by human T-lymphotropic virus-1 (HTLV-1) infection and mantle cell lymphoma (MCL)[1]. These findings suggest that TfR1-targeted approaches may prove particularly valuable for treating malignancies in which TfR1 is particularly highly expressed or functionally critical for survival. Additionally, researchers have exploited the TfR1 transcytosis pathway at the blood-brain barrier for delivery of anti-TfR1 antibody fusion proteins carrying therapeutic cargos to brain tissues, enabling treatment of central nervous system diseases including glioblastoma and other CNS malignancies[24][51].
Evolutionary Conservation and Comparative Biology
Structural Homology and Family Relationships
TfR1 belongs to the M28 family of zinc-dependent peptidases and shares structural homology with numerous peptidase family members, including glutamate carboxypeptidase II (GCP2, also called PSMA), N-acetylated alpha-linked acidic dipeptidase (NAALAD), and related proteins[45][49]. Despite this structural similarity to catalytically active peptidases, TfR1 itself is catalytically inactive, having diverged from peptidase family members through loss of critical catalytic residues while retaining the overall structural scaffold[43]. This apparent evolutionary conversion of an active peptidase domain into a ligand-binding domain demonstrates how evolution repurposes protein domains for novel functions while maintaining structural integrity[49]. The transfer receptor family in primates is represented by at least seven different homologous proteins, indicating repeated gene duplication events in vertebrate evolution, likely reflecting divergent specialization of these receptors for distinct biological roles[45].
Positive Selection and Species-Specific Adaptations
Comparative genomic analyses have revealed evidence for positive selection acting on the TFRC gene during the evolution of Caniformia (the clade including dogs and their relatives), suggesting that specific amino acid changes in TfR1 confer adaptive advantages in these species[48]. This evolutionary signature of positive selection on a receptor gene is relatively uncommon and suggests that changes in iron metabolism or iron sensing may have provided fitness advantages during caniform evolution, perhaps related to changes in dietary iron sources or metabolic rates[48]. Such evolutionary adaptation at TfR1 demonstrates that the specific sequence of this iron transport protein is subject to selective constraints and that functional optimization of TfR1 for each species' particular physiological requirements drives amino acid evolution[48].
Conclusions and Future Perspectives
Transferrin receptor protein 1 represents one of the most comprehensively characterized iron transport proteins, reflecting both its fundamental biological importance and its prominence as a therapeutic target. The sophisticated molecular mechanisms governing TfR1 functionâincluding pH-sensitive binding to transferrin with active promotion of iron release, rapid endocytic internalization through clathrin-dependent pathways, highly regulated recycling through Rab-mediated trafficking, and post-transcriptional control through iron-responsive elementsâdemonstrate the cellular investment in ensuring appropriate iron delivery matched to cellular needs. The protein's participation in diverse biological processes ranging from hemoglobin synthesis in erythroid precursors to iron sensing controlling systemic hepcidin production illustrates how a single receptor integrates multiple physiological signals to coordinate iron metabolism at cellular and organismal levels.
The emerging recognition of TfR1's roles beyond basic iron transportâincluding its function as a regulator of alternative splicing patterns, its involvement in viral cell entry, and its pathogenic role in autoimmune diseasesâsuggests that our understanding of this protein's biology remains incomplete. Future research employing structural biology, single-molecule studies, and system-wide approaches will likely reveal additional regulatory mechanisms and biological contexts in which TfR1 participates. The therapeutic potential of targeting TfR1 in cancer, leveraging the protein's abundant expression on rapidly dividing cells and the critical importance of iron for DNA synthesis, continues to drive drug development efforts that may provide effective treatments for otherwise intractable malignancies. As research deepens understanding of TfR1 biology and function, this protein will undoubtedly continue serving as a paradigm for understanding how cells precisely regulate nutrient acquisition in response to metabolic demands and environmental iron availability.
Citations
- https://en.wikipedia.org/wiki/Transferrin_receptor_1
- https://www.bio-rad-antibodies.com/cd71-iron-transport-markers-antibodies.html
- https://geneglobe.qiagen.com/us/knowledge/gene/ENSG00000072274
- https://www.uniprot.org/uniprotkb/P02786/entry
- https://pubmed.ncbi.nlm.nih.gov/16271884/
- https://www.ncbi.nlm.nih.gov/gene/7037
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3288267/
- https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=7037
- https://onlinelibrary.wiley.com/doi/10.1111/tra.70006?af=R
- https://www.nature.com/articles/s12276-025-01436-x
- https://www.uniprot.org/uniprotkb/A0A8V8TM46/entry
- https://arxiv.org/pdf/2412.14131.pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC498283/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4783254/
- https://www.rndsystems.com/resources/articles/soluble-transferrin-receptor-stfr
- https://www.proteinatlas.org/ENSG00000072274-TFRC/tissue
- https://ashpublications.org/blood/article/141/4/422/486971/Regulation-of-iron-homeostasis-by-hepatocyte-TfR1
- https://www.mayocliniclabs.com/test-catalog/overview/84283
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2840523/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2673483/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6175443/
- https://www.nature.com/articles/s41467-019-09098-w
- https://portlandpress.com/biochemj/article/373/1/145/43889/Evidence-for-the-interaction-of-the-hereditary
- https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.01019/full
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4036340/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC99597/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC401153/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4786429/
- https://www.nature.com/articles/s41392-023-01720-0
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4931119/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3459860/
- https://en.wikipedia.org/wiki/Iron_response_element
- https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1176118/full
- https://ashpublications.org/blood/article/140/10/1061/486472/Grab-and-go-transferrin-uptake-in-erythropoiesis
- https://medlineplus.gov/genetics/condition/hereditary-hemochromatosis/
- https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1567216/full
- https://pubmed.ncbi.nlm.nih.gov/33352721/
- https://www.ncbi.nlm.nih.gov/books/NBK1349/
- https://pubmed.ncbi.nlm.nih.gov/16510596/
- https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi?INPUT_TYPE=live&SEQUENCE=NP_003225.2
- https://g2p.broadinstitute.org/gene/TFRC
- https://pubmed.ncbi.nlm.nih.gov/17160644/
- https://www.ebi.ac.uk/merops/cgi-bin/pepsum?id=M28.972%3Btype%3DP
- https://journals.plos.org/plospathogens/article?id=10.1371%2Fjournal.ppat.1002666
- https://pubmed.ncbi.nlm.nih.gov/10531064/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7412275/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6512944/
- https://www.rcsb.org/structure/1cx8
- https://www.nature.com/articles/nature05539
- https://www.science.org/doi/10.1126/sciimmunol.abq0178
- https://www.pnas.org/doi/10.1073/pnas.0409719102
- https://www.pnas.org/doi/10.1073/pnas.2207461120
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2134874/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC413385/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3265927/
- https://www.pnas.org/doi/10.1073/pnas.1105786108